Company

XBiotech

XBIT biotech USA

Quick answer

XBiotech is a biotech company (XBIT) headquartered in AUSTIN, TX, USA with 8 tracked pipeline programs.

Pipeline (8)

514G3 (2 mg/kg) plus standard IV antibiotic treatment

Staphylococcus Aureus Bacteremia

Phase 2 · mab · completed

1 trials project

Natrunix

Rheumatoid Arthritis

Phase 2 · small_molecule · completed

1 trials project

Natrunix 400 mg

Rheumatoid Arthritis

Phase 2 · mab · active

1 trials project

Natrunix with MTX placebo (+folate)

Rheumatoid Arthritis

Phase 2 · small_molecule · active

1 trials project

XB2001 or Placebo

Pancreatic Cancer

Phase 2 · mab · active

1 trials project

vilamakitug

Axial Spondyloarthritis

Phase 2 · small_molecule · active

1 trials project

Hutrukin

Pharmacokinetics

Phase 1 · mab · completed

1 trials project

NatrunixTM

Pharmacokinetics

Phase 1 · mab · active

Patents (8)

US 12116405

Arthritis treatment

Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11932688

Treatment for neoplastic diseases

Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11773157

Compositions and methods for treating and preventing Staphylococcus aureus infec

Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11529298

Cosmetic composition and its use, dermocosmetic formulation

Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11523981

Cosmetic composition and its use, dermocosmetic formulation

Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11370831

Compositions and methods for treating and preventing Staphylococcus aureus infec

Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10577410

Compositions and methods for treating and preventing Staphylococcus aureus infec

Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

US 10294296

Treatment for neoplastic diseases

Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026